Medtronic (NYSE:MDT) plans to cease operations at its Santa Rosa, California, facility.
The Press Democrat reported that Medtronic plans to leave the location, which houses 370 employees, over the next two years. This move affects employees at the Fountaingrove campus (3540 and 3576 Unocal Place), the report said. It also reportedly impacts those who work remotely or on a hybrid basis in operations related to the Santa Rosa site.
According to the report, the medtech giant plans to relocate operations from Santa Rosa primarily to Santa Ana, Minnesota and Galway, Ireland. It expects to complete the process in spring 2028, with some roles set to depart next spring. The Press Democrat says Medtronic started the transition process to redeploy local workers and find opportunities for remote work or relocation.
Medtronic’s Santa Rosa site came to the company nearly three decades ago through its acquisition of Arterial Vascular Engineering. More than six years ago, the company shifted some operations from Santa Rosa to Massachusetts, laying off around 100 employees in the process.
The change comes as Medtronic undergoes another round of significant restructuring. That includes the separation of its MiniMed Diabetes business, which recently resulted in more than 80 layoffs in California. The company also announced the consolidation of its Cardiac Surgery and Aortic businesses into a single Cardiovascular Surgery unit.
According to The Minnesota Star Tribune, the latest restructuring move coincides with reports from employees of workforce reductions. Posts on LinkedIn suggest the company has recently enacted reductions, although WARN records in the main states where Medtronic operates don’t yet show large layoffs.
More info from Medtronic
A Medtronic spokesperson shared a statement with MassDevice via email outlining the rationale behind the recent restructuring and changes:
On the Cardiovascular Surgery consolidation:
“Our newly created CardioVascular Surgery business unit is designed to accelerate innovation within cardiac and aortic care by partnering closely with vascular, cardiothoracic, and cardiac specialists. The integration is intended to help us strengthen our focus and investment so we can continue to best serve patients across the entire continuum of cardiovascular care.
“As an additional effort to ensure we’re delivering maximum value to our customers and driving meaningful impact to patients, we also recently brought together our Structural Heart, Coronary, and Renal Denervation businesses to form Interventional Cardiology Therapies (ICT). We believe this new organizational approach will help us advance our strategy in these critical business areas.”
On the Santa Rosa closure:
On the site closure, that closure is not immediate:
“Medtronic regularly reviews its global operations to ensure we continue to meet the evolving needs of patients and healthcare providers while positioning the company for long-term growth. Following this review, we have made the difficult but strategic decision to close our Santa Rosa site in approximately two years. This decision is not a reflection of the outstanding, impactful work done in Santa Rosa. We are deeply proud of the contributions our employees have made here, which have advanced our mission, strengthened patient care, and positively impacted the community. As we navigate this transition, our priority is to support our employees throughout the process. We do not anticipate any impact to our customers.
“Regarding timing, we will start seeing employees depart in spring of 2027 with site closure in spring 2028.”
